Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas.

Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W, Kristiansen G.

Hum Pathol. 2009 Oct;40(10):1377-83. doi: 10.1016/j.humpath.2009.01.024. Epub 2009 May 20.

PMID:
19467694
2.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
3.

Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.

Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH.

Mod Pathol. 2007 Dec;20(12):1263-8. Epub 2007 Sep 21.

4.

Prognostic significance of fascin expression in extrahepatic bile duct carcinomas.

Won KY, Kim GY, Lim SJ, Park YK, Kim YW.

Pathol Res Pract. 2009;205(11):742-8. doi: 10.1016/j.prp.2009.05.009. Epub 2009 Jun 24.

PMID:
19556073
5.

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB.

Mod Pathol. 2009 Mar;22(3):469-75. doi: 10.1038/modpathol.2008.206. Epub 2009 Jan 9.

6.

IMP3 expression in human ovarian cancer is associated with improved survival.

Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C.

Int J Gynecol Pathol. 2009 May;28(3):203-10. doi: 10.1097/PGP.0b013e318189a724.

PMID:
19620937
7.

The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.

Am J Surg Pathol. 2008 Feb;32(2):304-15. doi: 10.1097/PAS.0b013e3181483ff8.

PMID:
18223334
8.

Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.

Riener MO, Vogetseder A, Pestalozzi BC, Clavien PA, Probst-Hensch N, Kristiansen G, Jochum W.

Hum Pathol. 2010 Nov;41(11):1558-65. doi: 10.1016/j.humpath.2009.12.016.

PMID:
20621328
9.

Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.

Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM.

Ann Surg Oncol. 2009 Jun;16(6):1711-9. doi: 10.1245/s10434-009-0446-0. Epub 2009 Apr 9.

PMID:
19357927
10.

Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A.

Endocr Pathol. 2009 Fall;20(3):149-57. doi: 10.1007/s12022-009-9079-x.

PMID:
19449140
11.

IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.

Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, Peng Z.

Ann Surg Oncol. 2009 Dec;16(12):3499-506. doi: 10.1245/s10434-009-0648-5.

PMID:
19672661
12.

Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts.

Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Cancer. 2001 Apr 1;91(7):1332-41.

PMID:
11283934
13.

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B.

Hum Pathol. 2009 Apr;40(4):527-37. doi: 10.1016/j.humpath.2008.10.003. Epub 2009 Jan 3.

PMID:
19121847
14.

Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.

Sung JY, Kim GY, Lim SJ, Park YK, Kim YW.

Pathol Res Pract. 2010 Jan 15;206(1):24-9. doi: 10.1016/j.prp.2009.07.018. Epub 2009 Oct 12.

PMID:
19819644
15.

Analysis of IMP3 expression in normal and neoplastic human pituitary tissues.

Righi A, Zhang S, Jin L, Scheithauer BW, Kovacs K, Kovacs G, Goth MI, Korbonits M, Lloyd RV.

Endocr Pathol. 2010 Mar;21(1):25-31. doi: 10.1007/s12022-009-9096-9.

PMID:
19898970
16.

IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.

Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z.

Clin Cancer Res. 2008 Mar 15;14(6):1701-6. doi: 10.1158/1078-0432.CCR-07-2039.

17.

IMP3 expression is correlated with histologic grade of lung adenocarcinoma.

Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H.

Hum Pathol. 2010 Apr;41(4):477-84. doi: 10.1016/j.humpath.2009.10.004. Epub 2009 Dec 11.

PMID:
20004948
18.

Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.

Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K, Oda Y, Shindo K, Fujino M, Tanaka M, Oda Y.

Hum Pathol. 2013 Sep;44(9):1714-21. doi: 10.1016/j.humpath.2012.12.020. Epub 2013 Apr 15.

PMID:
23597774
19.

Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.

Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G.

Histopathology. 2010 Apr;56(5):600-6. doi: 10.1111/j.1365-2559.2010.03527.x.

PMID:
20459570
20.

An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.

Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z.

Am J Surg Pathol. 2009 Apr;33(4):521-5. doi: 10.1097/PAS.0b013e31818aada9.

PMID:
19047899

Supplemental Content

Support Center